Board MeetingOutcome of Board Meeting
Vivimed Labs' board approved consolidated Q3 FY26 results: Revenue ₹159.89 Cr, Loss ₹16.55 Cr.
Vivimed Labs LimitedVIVIMEDLAB · Filed with the exchange
Auditors issued a qualified report, flagging unprovided loan interest, pending forensic audit impact, and unsupported commission provisions, significantly impacting reported figures. #VIVIMEDLAB
No comments yet. Be the first.